<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20240124131108
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20240124131108" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Wed, 24 Jan 2024 18:11:10 +0000</lastbuilddate>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Complex Genetic Architecture of Spontaneous Coronary Artery Dissection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38265841/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 24. doi: 10.1001/jamacardio.2023.5201. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38265841/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38265841</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5201>10.1001/jamacardio.2023.5201</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38265841</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Complex Genetic Architecture of Spontaneous Coronary Artery Dissection</dc:title>
<dc:identifier>pmid:38265841</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5201</dc:identifier>
</item>
<item>
<title>Advancing Data Collection of Sexual Orientation and Gender Identity in Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38265839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 24. doi: 10.1001/jamacardio.2023.5264. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38265839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38265839</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5264>10.1001/jamacardio.2023.5264</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38265839</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Nguyen K Tran</dc:creator>
<dc:creator>Nicole Rosendale</dc:creator>
<dc:creator>Mitchell R Lunn</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Advancing Data Collection of Sexual Orientation and Gender Identity in Cardiology</dc:title>
<dc:identifier>pmid:38265839</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5264</dc:identifier>
</item>
<item>
<title>Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38265835/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: The findings in this study support current guideline recommendations for use of sodium-glucose transport protein 2 inhibitor therapy, and further suggest that the addition of a sodium-glucose transport protein 2 inhibitor therapy to other guideline-directed medical therapies may help reduce cardiovascular mortality in patients with HFimpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 24. doi: 10.1001/jamacardio.2023.5318. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Heart failure with improved ejection fraction (HFimpEF), defined as prior left ventricular ejection fraction (LVEF) 40% or lower that has increased to greater than 40%, is understudied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine mode of death and the association of dapagliflozin with reductions in cause-specific death in patients with HFimpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis from the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial, conducted from August 2018 to December 2020. The trial randomly assigned patients with HF with LVEF greater than 40%, New York Heart Association class II to IV symptoms, and elevated natriuretic peptides to treatment with dapagliflozin (10 mg, once daily) or placebo. The presence of HFimpEF was captured through study case report forms. The primary outcome was a composite of worsening HF events (hospitalization or urgent HF visits) or cardiovascular death. Clinical outcomes were adjudicated by a blinded clinical end points committee. Data were analyzed from May 2022 to August 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Dapagliflozin vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The mode of death in relation to HFimpEF status was examined, as well as the association of randomized treatment with cause-specific death in Cox regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1151 patients with HFimpEF in DELIVER, 190 (16.5%) died, compared with 833 patients (16.3%) of 5112 with LVEF consistently greater than 40%. The overall distribution of mode of death was similar in those with HFimpEF compared with those with LVEF consistently greater than 40% (noncardiovascular death: 103 of 190 [54%] vs 428 of 833 [51%]; cardiovascular death: 87 of 190 [46%] vs 405 of 833 [49%], respectively). Most deaths in individuals with HFimpEF were noncardiovascular (103 of 180 [54%]). For cardiovascular deaths, sudden deaths were most common (36 of 190 events [19%]), followed by HF-related (29 of 190 events [15%]). Among patients with HFimpEF, treatment with dapagliflozin was associated with lower rates of cardiovascular death relative to placebo, a difference primarily due to lower rates of sudden death (hazard ratio, 0.38; 95% CI, 0.18-0.79; P for interaction = .01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The findings in this study support current guideline recommendations for use of sodium-glucose transport protein 2 inhibitor therapy, and further suggest that the addition of a sodium-glucose transport protein 2 inhibitor therapy to other guideline-directed medical therapies may help reduce cardiovascular mortality in patients with HFimpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38265835/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38265835</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5318>10.1001/jamacardio.2023.5318</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38265835</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Orly Vardeny</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>James C Fang</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Felipe A Martinez</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Finnian R Mc Causland</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial</dc:title>
<dc:identifier>pmid:38265835</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5318</dc:identifier>
</item>
<item>
<title>Recruiting a Diverse Cardiology Physician Workforce</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38265823/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: In this study, the representation of women in cardiovascular fellowships, including interventional cardiology, increased over recent years. While representation of Black and Hispanic individuals is low in all residencies, including cardiovascular fellowships, recent positive trends are important to recognize and provide hope to drive future efforts.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 24. doi: 10.1001/jamacardio.2023.5324. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Understanding trends in the representation of women and individuals from underrepresented racial and ethnic populations in cardiovascular disease and cardiovascular subspecialty fellowships is essential to improving the diversity of the cardiology workforce.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine changes in the representation of women and underrepresented individuals in cardiovascular disease and cardiovascular subspecialty fellowships over time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study of trainee sex and race and ethnicity in various training programs from 2008 to 2022 used data from the Accreditation Council for Graduate Medical Education's publicly available online source. Participants included all residents, internal medicine residents, general surgery residents, and fellows in cardiovascular disease and cardiovascular subspecialty fellowships.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Percentages of women and Black and Hispanic trainees in these programs were calculated for each year. Mann-Kendall tests were used to determine if changes over the years represented a significant trend.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the 3320 cardiovascular disease trainees in 2022, 848 (25.5%) were women, and 459 (13.8%) were Black or Hispanic, less than the representation among internal medicine trainees at 43.8% and 15.6%, respectively. However, the percentage of women trainees in cardiovascular disease significantly increased from 17.6% in 2008 (P = .001 for time trend) and also increased for interventional cardiology fellowships (from 6.3% in 2008 to 20.1% in 2022; P = .002). Over the same period, the proportion of women in general surgery increased from 27.4% to 45.2% (P &lt; .001). The percentage of Black and Hispanic trainees in internal medicine significantly increased from 8.6% in 2012 (P &lt; .001) while increases in general surgery were not statistically significant (9.7% to 16.1%; P = .35). There were also important increases in the percentages of Black and Hispanic trainees in cardiovascular disease (from 8.3% in 2012; P = .09) and interventional cardiology (3.8% to 13.4%; P = .12).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, the representation of women in cardiovascular fellowships, including interventional cardiology, increased over recent years. While representation of Black and Hispanic individuals is low in all residencies, including cardiovascular fellowships, recent positive trends are important to recognize and provide hope to drive future efforts.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38265823/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38265823</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5324>10.1001/jamacardio.2023.5324</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38265823</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Sarah C Snow</dc:creator>
<dc:creator>Brooke Alhanti</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Recruiting a Diverse Cardiology Physician Workforce</dc:title>
<dc:identifier>pmid:38265823</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5324</dc:identifier>
</item>
<item>
<title>Polygenic Risk in Families With Spontaneous Coronary Artery Dissection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38265806/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: Extreme aggregation of common genetic risk appears to play a significant role in familial clustering of SCAD as well as in sporadic case predisposition, although further study is required.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 24. doi: 10.1001/jamacardio.2023.5194. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Spontaneous coronary artery dissection (SCAD) is a poorly understood cause of acute coronary syndrome that predominantly affects women. Evidence to date suggests a complex genetic architecture, while a family history is reported for a minority of cases.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the contribution of rare and common genetic variants to SCAD risk in familial cases, the latter via the comparison of a polygenic risk score (PRS) with those with sporadic SCAD and healthy controls.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This genetic association study analyzed families with SCAD, individuals with sporadic SCAD, and healthy controls. Genotyping was undertaken for all participants. Participants were recruited between 2017 and 2021. A PRS for SCAD was calculated for all participants. The presence of rare variants in genes associated with connective tissue disorders (CTD) was also assessed. Individuals with SCAD were recruited via social media or from a single medical center. A previously published control database of older healthy individuals was used. Data were analyzed from January 2022 to October 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: PRS for SCAD comprised of 7 single-nucleotide variants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Disease status (familial SCAD, sporadic SCAD, or healthy control) associated with PRS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 13 families with SCAD (27 affected and 12 unaffected individuals), 173 individuals with sporadic SCAD, and 1127 healthy controls were included. A total of 188 individuals with SCAD (94.0%) were female, including 25 of 27 with familial SCAD and 163 of 173 with sporadic SCAD; of 12 unaffected individuals from families with SCAD, 6 (50%) were female; and of 1127 healthy controls, 672 (59.6%) were female. Compared with healthy controls, the odds of being an affected family member or having sporadic SCAD was significantly associated with a SCAD PRS (where the odds ratio [OR] represents an increase in odds per 1-SD increase in PRS) (affected family member: OR, 2.14; 95% CI, 1.78-2.50; adjusted P = 1.96 × 10-4; sporadic SCAD: OR, 1.63; 95% CI, 1.37-1.89; adjusted P = 5.69 × 10-4). This association was not seen for unaffected family members (OR, 1.03; 95% CI, 0.46-1.61; adjusted P = .91) compared with controls. Further, those with familial SCAD were overrepresented in the top quintile of the control PRS distribution (OR, 3.70; 95% CI, 2.93-4.47; adjusted P = .001); those with sporadic SCAD showed a similar pattern (OR, 2.51; 95% CI, 1.98-3.04; adjusted P = .001). Affected individuals within a family did not share any rare deleterious variants in CTD-associated genes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Extreme aggregation of common genetic risk appears to play a significant role in familial clustering of SCAD as well as in sporadic case predisposition, although further study is required.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38265806/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38265806</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5194>10.1001/jamacardio.2023.5194</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38265806</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Ingrid Tarr</dc:creator>
<dc:creator>Stephanie Hesselson</dc:creator>
<dc:creator>Michael Troup</dc:creator>
<dc:creator>Paul Young</dc:creator>
<dc:creator>Jamie-Lee Thompson</dc:creator>
<dc:creator>Lucy McGrath-Cadell</dc:creator>
<dc:creator>Diane Fatkin</dc:creator>
<dc:creator>Sally L Dunwoodie</dc:creator>
<dc:creator>David W M Muller</dc:creator>
<dc:creator>Siiri E Iismaa</dc:creator>
<dc:creator>Jason C Kovacic</dc:creator>
<dc:creator>Robert M Graham</dc:creator>
<dc:creator>Eleni Giannoulatou</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Polygenic Risk in Families With Spontaneous Coronary Artery Dissection</dc:title>
<dc:identifier>pmid:38265806</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5194</dc:identifier>
</item>
<item>
<title>Education and Information to Improve Cardiovascular Health-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38265786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 24. doi: 10.1001/jamacardio.2023.5248. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38265786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38265786</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5248>10.1001/jamacardio.2023.5248</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38265786</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Gloria Santos-Beneit</dc:creator>
<dc:creator>Rodrigo Fernández-Jiménez</dc:creator>
<dc:creator>Valentín Fuster</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Education and Information to Improve Cardiovascular Health-Reply</dc:title>
<dc:identifier>pmid:38265786</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5248</dc:identifier>
</item>
<item>
<title>Emphasizing Sexual Orientation and Gender Identity Data Capture for Improved Cardiovascular Care of the LGBTQ+ Population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38265768/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: Potential solutions for improving much-needed SOGIE data collection include (1) implementing LGBTQ+ inclusive policies, (2) integrating SOGIE data into the EHR, (3) educating health care professionals on the relevance of SOGIE to patient-centered care, and (4) creating a diverse cardiovascular workforce. These steps can substantially enhance the ability to collect SOGIE data to address LGBTQ+ cardiovascular health care disparities.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 24. doi: 10.1001/jamacardio.2023.5267. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The rising self-identifying lesbian, gay, bisexual, transgender, and queer (LGBTQ+) population makes understanding the unique health care needs of sexual and gender minoritized patients an urgent one. The interaction between minority stress and cardiovascular disease has been well described among underrepresented minoritized populations. The underrepresentation of minoritized populations in clinical research is partly responsible for worse cardiovascular outcomes in these populations. The absence of sexual orientation and gender identity and expression (SOGIE) data makes it difficult to understand the cardiovascular health of LGBTQ+ adults, thereby widening health care disparities in this population. Advancing cardiovascular health equity for LGBTQ+ patients must begin with careful and accurate SOGIE data collection.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBSERVATIONS: Current SOGIE data capture remains inadequate despite federal mandates. Challenges in data collection include political and regulatory discrimination, patient/practitioner hesitancy, lack of supportive guidance on SOGIE data collection, improper terminology, regulatory inertia, and inadequate and often incorrect integration of SOGIE data into electronic health records (EHRs). Additional challenges include grouping participants as "others" for statistical significance. The inclusion of SOGIE data has demonstrated an impact in other fields like cancer survivorship and surgery. The same needs to be done for cardiology.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Potential solutions for improving much-needed SOGIE data collection include (1) implementing LGBTQ+ inclusive policies, (2) integrating SOGIE data into the EHR, (3) educating health care professionals on the relevance of SOGIE to patient-centered care, and (4) creating a diverse cardiovascular workforce. These steps can substantially enhance the ability to collect SOGIE data to address LGBTQ+ cardiovascular health care disparities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38265768/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38265768</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5267>10.1001/jamacardio.2023.5267</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38265768</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Brototo Deb</dc:creator>
<dc:creator>Kadijah Porter</dc:creator>
<dc:creator>Ashlan van Cleeff</dc:creator>
<dc:creator>Leigh C Reardon</dc:creator>
<dc:creator>Stephen Cook</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Emphasizing Sexual Orientation and Gender Identity Data Capture for Improved Cardiovascular Care of the LGBTQ+ Population</dc:title>
<dc:identifier>pmid:38265768</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5267</dc:identifier>
</item>
<item>
<title>Education and Information to Improve Cardiovascular Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38265766/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 24. doi: 10.1001/jamacardio.2023.5251. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38265766/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38265766</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5251>10.1001/jamacardio.2023.5251</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38265766</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Antonio V Sterpetti</dc:creator>
<dc:creator>Luca Di Marzo</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Education and Information to Improve Cardiovascular Health</dc:title>
<dc:identifier>pmid:38265766</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5251</dc:identifier>
</item>
<item>
<title>Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of Four Randomized Clinical Trials of 58 464 Patients With Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38264923/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>CONCLUSIONS: The treatment effect of NOAC versus warfarin in atrial fibrillation is generally consistent for stroke/SEE across the spectrum of BMI and BW, whereas the reduction in major bleeding is attenuated at a higher BMI and BW. Death and the net clinical outcome are reduced with NOACs versus warfarin overall, although there remain uncertainties for these outcomes at a very high BMI and BW.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 24. doi: 10.1161/CIRCULATIONAHA.123.066279. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The efficacy and safety of non-vitamin-K antagonist oral anticoagulants (NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We analyzed data from COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation), which pooled patient-level data from the 4 pivotal randomized trials of NOAC versus warfarin in patients with atrial fibrillation. The primary efficacy and safety outcomes were stroke or systemic embolic events (stroke/SEE) and major bleeding, respectively; secondary outcomes were ischemic stroke/SEE, intracranial hemorrhage, death, and the net clinical outcome (stroke/SEE, major bleeding, or death). Each outcome was examined across BMI and BW. Because few patients had a BMI &lt;18.5 kg/m<sup>2</sup> (n=598), the primary analyses were restricted to those with a BMI ≥18.5 kg/m<sup>2</sup>.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 58 464 patients, the median BMI was 28.3 (interquartile range, 25.2-32.2) kg/m<sup>2</sup>, and the median BW was 81.0 (interquartile range, 70.0-94.3) kg. The event probability of stroke/SEE was lower at a higher BMI irrespective of treatment, whereas the probability of major bleeding was lower at a higher BMI with warfarin but relatively unchanged across a BMI with an NOAC. NOACs reduced stroke/SEE overall (HR<sub>adj</sub>, 0.80 [95% CI, 0.73-0.88]; <i>P</i>&lt;0.001), with a generally consistent effect across BMI (<i>P</i><sub>trend</sub> across HRs, 0.48). NOACs also reduced major bleeding overall (HR<sub>adj</sub>, 0.88 [95% CI, 0.82-0.94]; <i>P</i>&lt;0.001), but with attenuation of the benefit at a higher BMI (<i>P</i><sub>trend</sub>, 0.003). The overall treatment effects of an NOAC versus warfarin for secondary outcomes were consistent across BMI, with the exception of the net clinical outcome and death, which, although was reduced overall with an NOAC (net clinical outcome, HR<sub>adj</sub>, 0.91 [95% CI, 0.87-0.95]; <i>P</i>&lt;0.001; death, HR<sub>adj</sub>, 0.91 [95% CI, 0.86-0.97]; <i>P</i>=0.003), tended to favor warfarin at a higher BMI (<i>P</i><sub>trend</sub>, 0.001 and 0.08, respectively). This finding was not explained by differences in ischemic or fatal bleeding events. All findings were qualitatively similar when analyzed across BW.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The treatment effect of NOAC versus warfarin in atrial fibrillation is generally consistent for stroke/SEE across the spectrum of BMI and BW, whereas the reduction in major bleeding is attenuated at a higher BMI and BW. Death and the net clinical outcome are reduced with NOACs versus warfarin overall, although there remain uncertainties for these outcomes at a very high BMI and BW.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38264923/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38264923</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066279>10.1161/CIRCULATIONAHA.123.066279</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38264923</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Siddharth M Patel</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Jan Steffel</dc:creator>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>Michael G Palazzolo</dc:creator>
<dc:creator>Elliott M Antman</dc:creator>
<dc:creator>Erin A Bohula</dc:creator>
<dc:creator>Anthony P Carnicelli</dc:creator>
<dc:creator>Stuart J Connolly</dc:creator>
<dc:creator>John Eikelboom</dc:creator>
<dc:creator>Baris Gencer</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Lars Wallentin</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:creator>Robert P Giugliano</dc:creator>
<dc:creator>COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of Four Randomized Clinical Trials of 58 464 Patients With Atrial Fibrillation</dc:title>
<dc:identifier>pmid:38264923</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066279</dc:identifier>
</item>
<item>
<title>2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38264914/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 24. doi: 10.1161/CIR.0000000000001209. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome) that contribute to cardiovascular health. The AHA Heart Disease and Stroke Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, brain health, complications of pregnancy, kidney disease, congenital heart disease, rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary heart disease, cardiomyopathy, heart failure, valvular disease, venous thromboembolism, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing. The 2024 AHA Statistical Update is the product of a full year's worth of effort in 2023 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members. The AHA strives to further understand and help heal health problems inflicted by structural racism, a public health crisis that can significantly damage physical and mental health and perpetuate disparities in access to health care, education, income, housing, and several other factors vital to healthy lives. This year's edition includes additional global data, as well as data on the monitoring and benefits of cardiovascular health in the population, with an enhanced focus on health equity across several key domains.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Each of the chapters in the Statistical Update focuses on a different topic related to heart disease and stroke statistics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38264914/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38264914</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001209>10.1161/CIR.0000000000001209</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38264914</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Seth S Martin</dc:creator>
<dc:creator>Aaron W Aday</dc:creator>
<dc:creator>Zaid I Almarzooq</dc:creator>
<dc:creator>Cheryl A M Anderson</dc:creator>
<dc:creator>Pankaj Arora</dc:creator>
<dc:creator>Christy L Avery</dc:creator>
<dc:creator>Carissa M Baker-Smith</dc:creator>
<dc:creator>Bethany Barone Gibbs</dc:creator>
<dc:creator>Andrea Z Beaton</dc:creator>
<dc:creator>Amelia K Boehme</dc:creator>
<dc:creator>Yvonne Commodore-Mensah</dc:creator>
<dc:creator>Maria E Currie</dc:creator>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>Kelly R Evenson</dc:creator>
<dc:creator>Giuliano Generoso</dc:creator>
<dc:creator>Debra G Heard</dc:creator>
<dc:creator>Swapnil Hiremath</dc:creator>
<dc:creator>Michelle C Johansen</dc:creator>
<dc:creator>Rizwan Kalani</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>Darae Ko</dc:creator>
<dc:creator>Junxiu Liu</dc:creator>
<dc:creator>Jared W Magnani</dc:creator>
<dc:creator>Erin D Michos</dc:creator>
<dc:creator>Michael E Mussolino</dc:creator>
<dc:creator>Sankar D Navaneethan</dc:creator>
<dc:creator>Nisha I Parikh</dc:creator>
<dc:creator>Sarah M Perman</dc:creator>
<dc:creator>Remy Poudel</dc:creator>
<dc:creator>Mary Rezk-Hanna</dc:creator>
<dc:creator>Gregory A Roth</dc:creator>
<dc:creator>Nilay S Shah</dc:creator>
<dc:creator>Marie-Pierre St-Onge</dc:creator>
<dc:creator>Evan L Thacker</dc:creator>
<dc:creator>Connie W Tsao</dc:creator>
<dc:creator>Sarah M Urbut</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:creator>Jenifer H Voeks</dc:creator>
<dc:creator>Nae-Yuh Wang</dc:creator>
<dc:creator>Nathan D Wong</dc:creator>
<dc:creator>Sally S Wong</dc:creator>
<dc:creator>Kristine Yaffe</dc:creator>
<dc:creator>Latha P Palaniappan</dc:creator>
<dc:creator>American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association</dc:title>
<dc:identifier>pmid:38264914</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001209</dc:identifier>
</item>
<item>
<title>Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38264909/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>CONCLUSIONS: Our findings reveal that IPA protects against diastolic dysfunction in HFpEF by enhancing the nicotinamide adenine dinucleotide salvage pathway, suggesting the possibility of therapeutic management by either altering the gut microbiome composition or supplementing the diet with IPA.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 24. doi: 10.1161/CIRCRESAHA.123.322381. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a common but poorly understood form of heart failure, characterized by impaired diastolic function. It is highly heterogeneous with multiple comorbidities, including obesity and diabetes, making human studies difficult.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Metabolomic analyses in a mouse model of HFpEF showed that levels of indole-3-propionic acid (IPA), a metabolite produced by gut bacteria from tryptophan, were reduced in the plasma and heart tissue of HFpEF mice as compared with controls. We then examined the role of IPA in mouse models of HFpEF as well as 2 human HFpEF cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The protective role and therapeutic effects of IPA were confirmed in mouse models of HFpEF using IPA dietary supplementation. IPA attenuated diastolic dysfunction, metabolic remodeling, oxidative stress, inflammation, gut microbiota dysbiosis, and intestinal epithelial barrier damage. In the heart, IPA suppressed the expression of NNMT (nicotinamide N-methyl transferase), restored nicotinamide, NAD<sup>+</sup>/NADH, and SIRT3 (sirtuin 3) levels. IPA mediates the protective effects on diastolic dysfunction, at least in part, by promoting the expression of SIRT3. SIRT3 regulation was mediated by IPA binding to the aryl hydrocarbon receptor, as <i>Sirt3</i> knockdown diminished the effects of IPA on diastolic dysfunction in vivo. The role of the nicotinamide adenine dinucleotide circuit in HFpEF was further confirmed by nicotinamide supplementation, <i>Nnmt</i> knockdown, and <i>Nnmt</i> overexpression in vivo. IPA levels were significantly reduced in patients with HFpEF in 2 independent human cohorts, consistent with a protective function in humans, as well as mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings reveal that IPA protects against diastolic dysfunction in HFpEF by enhancing the nicotinamide adenine dinucleotide salvage pathway, suggesting the possibility of therapeutic management by either altering the gut microbiome composition or supplementing the diet with IPA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38264909/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38264909</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322381>10.1161/CIRCRESAHA.123.322381</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38264909</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yu-Chen Wang</dc:creator>
<dc:creator>Yen Chin Koay</dc:creator>
<dc:creator>Calvin Pan</dc:creator>
<dc:creator>Zhiqiang Zhou</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Jennifer Wilcox</dc:creator>
<dc:creator>Xinmin S Li</dc:creator>
<dc:creator>Alexia Zagouras</dc:creator>
<dc:creator>Francine Marques</dc:creator>
<dc:creator>Hooman Allayee</dc:creator>
<dc:creator>Federico E Rey</dc:creator>
<dc:creator>David M Kaye</dc:creator>
<dc:creator>John F O'Sullivan</dc:creator>
<dc:creator>Stanley L Hazen</dc:creator>
<dc:creator>Yang Cao</dc:creator>
<dc:creator>Aldons J Lusis</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:38264909</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322381</dc:identifier>
</item>
<item>
<title>Interruption of oral anticoagulants after atrial fibrillation catheter ablation: the importance of risk stratification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38263516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 23:ehad874. doi: 10.1093/eurheartj/ehad874. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38263516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38263516</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad874>10.1093/eurheartj/ehad874</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38263516</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Stephen Brienesse</dc:creator>
<dc:creator>Rod Passman</dc:creator>
<dc:creator>Ben Freedman</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Interruption of oral anticoagulants after atrial fibrillation catheter ablation: the importance of risk stratification</dc:title>
<dc:identifier>pmid:38263516</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad874</dc:identifier>
</item>
<item>
<title>Massive myocardial calcification as an aetiology of heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38263485/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 23:ehae009. doi: 10.1093/eurheartj/ehae009. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38263485/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38263485</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae009>10.1093/eurheartj/ehae009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38263485</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Marta Catarina Bernardo</dc:creator>
<dc:creator>Sofia Silva Carvalho</dc:creator>
<dc:creator>Ilídio Moreira</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Massive myocardial calcification as an aetiology of heart failure</dc:title>
<dc:identifier>pmid:38263485</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae009</dc:identifier>
</item>
<item>
<title>The role of the molecular autopsy in sudden cardiac death in young individuals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38263459/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 23. doi: 10.1038/s41569-024-00989-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38263459/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38263459</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00989-0>10.1038/s41569-024-00989-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38263459</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Julia C Isbister</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The role of the molecular autopsy in sudden cardiac death in young individuals</dc:title>
<dc:identifier>pmid:38263459</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00989-0</dc:identifier>
</item>
<item>
<title>Partial heart transplantation: a new option for paediatric heart valve replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38263458/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 23. doi: 10.1038/s41569-024-00991-6. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38263458/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38263458</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00991-6>10.1038/s41569-024-00991-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38263458</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Taufiek K Rajab</dc:creator>
<dc:creator>Andrew D Vogel</dc:creator>
<dc:creator>Joseph W Turek</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Partial heart transplantation: a new option for paediatric heart valve replacement</dc:title>
<dc:identifier>pmid:38263458</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00991-6</dc:identifier>
</item>
<item>
<title>Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38263457/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 23. doi: 10.1038/s41569-024-00993-4. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38263457/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38263457</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00993-4>10.1038/s41569-024-00993-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38263457</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy</dc:title>
<dc:identifier>pmid:38263457</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00993-4</dc:identifier>
</item>
<item>
<title>Cell surface RNAs control neutrophil recruitment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38262409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>RNAs localizing to the outer cell surface have been recently identified in mammalian cells, including RNAs with glycan modifications known as glycoRNAs. However, the functional significance of cell surface RNAs and their production are poorly known. We report that cell surface RNAs are critical for neutrophil recruitment and that the mammalian homologs of the sid-1 RNA transporter are required for glycoRNA expression. Cell surface RNAs can be readily detected in murine neutrophils, the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 17:S0092-8674(23)01443-5. doi: 10.1016/j.cell.2023.12.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RNAs localizing to the outer cell surface have been recently identified in mammalian cells, including RNAs with glycan modifications known as glycoRNAs. However, the functional significance of cell surface RNAs and their production are poorly known. We report that cell surface RNAs are critical for neutrophil recruitment and that the mammalian homologs of the sid-1 RNA transporter are required for glycoRNA expression. Cell surface RNAs can be readily detected in murine neutrophils, the elimination of which substantially impairs neutrophil recruitment to inflammatory sites in vivo and reduces neutrophils' adhesion to and migration through endothelial cells. Neutrophil glycoRNAs are predominantly on cell surface, important for neutrophil-endothelial interactions, and can be recognized by P-selectin (Selp). Knockdown of the murine Sidt genes abolishes neutrophil glycoRNAs and functionally mimics the loss of cell surface RNAs. Our data demonstrate the biological importance of cell surface glycoRNAs and highlight a noncanonical dimension of RNA-mediated cellular functions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38262409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38262409</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.033>10.1016/j.cell.2023.12.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38262409</guid>
<pubDate>Tue, 23 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Ningning Zhang</dc:creator>
<dc:creator>Wenwen Tang</dc:creator>
<dc:creator>Lidiane Torres</dc:creator>
<dc:creator>Xujun Wang</dc:creator>
<dc:creator>Yasmeen Ajaj</dc:creator>
<dc:creator>Li Zhu</dc:creator>
<dc:creator>Yi Luan</dc:creator>
<dc:creator>Hongyue Zhou</dc:creator>
<dc:creator>Yadong Wang</dc:creator>
<dc:creator>Dingyao Zhang</dc:creator>
<dc:creator>Vadim Kurbatov</dc:creator>
<dc:creator>Sajid A Khan</dc:creator>
<dc:creator>Priti Kumar</dc:creator>
<dc:creator>Andres Hidalgo</dc:creator>
<dc:creator>Dianqing Wu</dc:creator>
<dc:creator>Jun Lu</dc:creator>
<dc:date>2024-01-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Cell surface RNAs control neutrophil recruitment</dc:title>
<dc:identifier>pmid:38262409</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.033</dc:identifier>
</item>
<item>
<title>DNA-guided transcription factor cooperativity shapes face and limb mesenchyme</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38262408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>Transcription factors (TFs) can define distinct cellular identities despite nearly identical DNA-binding specificities. One mechanism for achieving regulatory specificity is DNA-guided TF cooperativity. Although in vitro studies suggest that it may be common, examples of such cooperativity remain scarce in cellular contexts. Here, we demonstrate how "Coordinator," a long DNA motif composed of common motifs bound by many basic helix-loop-helix (bHLH) and homeodomain (HD) TFs, uniquely defines the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 17:S0092-8674(23)01438-1. doi: 10.1016/j.cell.2023.12.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Transcription factors (TFs) can define distinct cellular identities despite nearly identical DNA-binding specificities. One mechanism for achieving regulatory specificity is DNA-guided TF cooperativity. Although in vitro studies suggest that it may be common, examples of such cooperativity remain scarce in cellular contexts. Here, we demonstrate how "Coordinator," a long DNA motif composed of common motifs bound by many basic helix-loop-helix (bHLH) and homeodomain (HD) TFs, uniquely defines the regulatory regions of embryonic face and limb mesenchyme. Coordinator guides cooperative and selective binding between the bHLH family mesenchymal regulator TWIST1 and a collective of HD factors associated with regional identities in the face and limb. TWIST1 is required for HD binding and open chromatin at Coordinator sites, whereas HD factors stabilize TWIST1 occupancy at Coordinator and titrate it away from HD-independent sites. This cooperativity results in the shared regulation of genes involved in cell-type and positional identities and ultimately shapes facial morphology and evolution.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38262408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38262408</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.032>10.1016/j.cell.2023.12.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38262408</guid>
<pubDate>Tue, 23 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Seungsoo Kim</dc:creator>
<dc:creator>Ekaterina Morgunova</dc:creator>
<dc:creator>Sahin Naqvi</dc:creator>
<dc:creator>Seppe Goovaerts</dc:creator>
<dc:creator>Maram Bader</dc:creator>
<dc:creator>Mervenaz Koska</dc:creator>
<dc:creator>Alexander Popov</dc:creator>
<dc:creator>Christy Luong</dc:creator>
<dc:creator>Angela Pogson</dc:creator>
<dc:creator>Tomek Swigut</dc:creator>
<dc:creator>Peter Claes</dc:creator>
<dc:creator>Jussi Taipale</dc:creator>
<dc:creator>Joanna Wysocka</dc:creator>
<dc:date>2024-01-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>DNA-guided transcription factor cooperativity shapes face and limb mesenchyme</dc:title>
<dc:identifier>pmid:38262408</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.032</dc:identifier>
</item>
<item>
<title>Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38258605/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>CONCLUSIONS: Overall use of optimal GDMT after HFrEF diagnosis was low, with significantly lower use among female (compared with male) patients. These findings highlight the need for implementation efforts directed at improving GDMT initiation and titration.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 23. doi: 10.1161/CIRCULATIONAHA.123.067489. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Guideline-directed medical therapies (GDMTs) are the mainstay of treatment for heart failure with reduced ejection fraction (HFrEF), but they are underused. Whether sex differences exist in the initiation and intensification of GDMT for newly diagnosed HFrEF is not well established.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with incident HFrEF were identified from the 2016 to 2020 Optum deidentified Clinformatics Data Mart Database, which is derived from a database of administrative health claims for members of large commercial and Medicare Advantage health plans. The primary outcome was the use of optimal GDMT within 12 months of HFrEF diagnosis. Consistent with the guideline recommendations during the time period of the study, optimal GDMT was defined as ≥50% of the target dose of evidence-based beta-blocker plus ≥50% of the target dose of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, or any dose of angiotensin receptor neprilysin inhibitor plus any dose of mineralocorticoid receptor antagonist. The probability of achieving optimal GDMT on follow-up and predictors of optimal GDMT were evaluated with time-to-event analysis with adjusted Cox proportional hazard models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study cohort included 63 759 patients (mean age, 71.3 years; 15.2% non-Hispanic Black race; 56.6% male). Optimal GDMT use was achieved by 6.2% of patients at 12 months after diagnosis. Female (compared with male) patients with HFrEF had lower use across every GDMT class and lower use of optimal GDMT at each time point at follow-up. In an adjusted Cox model, female sex was associated with a 23% lower probability of achieving optimal GDMT after diagnosis (hazard ratio [HR], 0.77 [95% CI, 0.71-0.83]; <i>P</i>&lt;0.001). The sex disparities in GDMT use after HFrEF diagnosis were most pronounced among patients with commercial insurance (females compared with males; HR, 0.66 [95% CI, 0.58-0.76]) compared with Medicare (HR, 0.85 [95% CI, 0.77-0.92]); <i>P</i><sub>interaction</sub> sex×insurance status=0.005) and for younger patients (age &lt;65 years: HR, 0.65 [95% CI, 0.58-0.74]) compared with older patients (age ≥65 years: HR, 87 [95% CI, 80-96]) <i>P</i><sub>interaction</sub> sex×age=0.009).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Overall use of optimal GDMT after HFrEF diagnosis was low, with significantly lower use among female (compared with male) patients. These findings highlight the need for implementation efforts directed at improving GDMT initiation and titration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38258605/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38258605</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067489>10.1161/CIRCULATIONAHA.123.067489</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38258605</guid>
<pubDate>Tue, 23 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Andrew Sumarsono</dc:creator>
<dc:creator>Luyu Xie</dc:creator>
<dc:creator>Neil Keshvani</dc:creator>
<dc:creator>Chenguang Zhang</dc:creator>
<dc:creator>LajjaBen Patel</dc:creator>
<dc:creator>Windy Alonso</dc:creator>
<dc:creator>Jennifer Thibodeau</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:creator>Sarah E Messiah</dc:creator>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:date>2024-01-23</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction</dc:title>
<dc:identifier>pmid:38258605</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067489</dc:identifier>
</item>
<item>
<title>&lt;em>;Apolipoprotein E&lt;/em>;-ε2 and Resistance to Atherosclerosis in Midlife-The PESA Observational Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38258600/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>CONCLUSIONS: This work sheds light on the role of APOE in cardiovascular disease development with important therapeutic and prevention implications on cardiovascular health, especially in early midlife.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 23. doi: 10.1161/CIRCRESAHA.123.323921. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: APOE is a known genetic contributor to cardiovascular disease, but the differential role <i>APOE</i> alleles play in subclinical atherosclerosis remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The PESA (Progression of Early Subclinical Atherosclerosis) is an observational cohort study that recruited 4184 middle-aged asymptomatic individuals to be screened for cardiovascular risk and multiterritorial subclinical atherosclerosis. Participants were <i>APOE</i>-genotyped, and omics data were additionally evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the PESA study, the frequencies for <i>APOE</i> -ε2, -ε3, and -ε4 alleles were 0.060, 0.844, and 0.096, respectively. This study included a subcohort of 3887 participants (45.8±4.3 years of age; 62% males). As expected, <i>APOE</i>-ε4 carriers were at the highest risk for cardiovascular disease and had significantly greater odds of having subclinical atherosclerosis compared with ε3/ε3 carriers, which was mainly explained by their higher levels of LDL (low-density lipoprotein)-cholesterol. In turn, <i>APOE</i>-ε2 carriers were at the lowest risk for cardiovascular disease and had significantly lower odds of having subclinical atherosclerosis in several vascular territories (carotids: 0.62 [95% CI, 0.47-0.81]; <i>P</i>=0.00043; femorals: 0.60 [0.47-0.78]; <i>P</i>=9.96×10<sup>-</sup><sup>5</sup>; coronaries: 0.53 [0.39-0.74]; <i>P</i>=0.00013; and increased PESA score: 0.58 [0.48-0.71]; <i>P</i>=3.16×10<sup>-</sup><sup>8</sup>). This <i>APOE</i>-ε2 atheroprotective effect was mostly independent of the associated lower LDL (low-density lipoprotein)-cholesterol levels and other cardiovascular risk factors. The protection conferred by the ε2 allele was greater with age (50-54 years: 0.49 [95% CI, 0.32-0.73]; <i>P</i>=0.00045), and normal (&lt;150 mg/dL) levels of triglycerides (0.54 [0.44-0.66]; <i>P</i>=4.70×10<sup>-</sup><sup>9</sup> versus 0.90 [0.57-1.43]; <i>P</i>=0.67 if ≥150 mg/dL). Omics analysis revealed an enrichment of several canonical pathways associated with anti-inflammatory mechanisms together with the modulation of erythrocyte homeostasis, coagulation, and complement activation in ε2 carriers that might play a relevant role in the ε2's atheroprotective effect.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This work sheds light on the role of APOE in cardiovascular disease development with important therapeutic and prevention implications on cardiovascular health, especially in early midlife.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov: NCT01410318.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38258600/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38258600</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323921>10.1161/CIRCRESAHA.123.323921</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38258600</guid>
<pubDate>Tue, 23 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Raquel Toribio-Fernández</dc:creator>
<dc:creator>Catarina Tristão-Pereira</dc:creator>
<dc:creator>Juan Carlos Silla-Castro</dc:creator>
<dc:creator>Sergio Callejas</dc:creator>
<dc:creator>Belen Oliva</dc:creator>
<dc:creator>Irene Fernandez-Nueda</dc:creator>
<dc:creator>Ines Garcia-Lunar</dc:creator>
<dc:creator>Cristina Perez-Herreras</dc:creator>
<dc:creator>José María Ordovás</dc:creator>
<dc:creator>Pilar Martin</dc:creator>
<dc:creator>Fiona Blanco-Kelly</dc:creator>
<dc:creator>Carmen Ayuso</dc:creator>
<dc:creator>Enrique Lara-Pezzi</dc:creator>
<dc:creator>Antonio Fernandez-Ortiz</dc:creator>
<dc:creator>Ana Garcia-Alvarez</dc:creator>
<dc:creator>Ana Dopazo</dc:creator>
<dc:creator>Fatima Sanchez-Cabo</dc:creator>
<dc:creator>Borja Ibanez</dc:creator>
<dc:creator>Marta Cortes-Canteli</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-01-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>&lt;em>;Apolipoprotein E&lt;/em>;-ε2 and Resistance to Atherosclerosis in Midlife-The PESA Observational Study</dc:title>
<dc:identifier>pmid:38258600</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323921</dc:identifier>
</item>
<item>
<title>AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38258575/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240124131108&amp;v=2.18.0
      <description>CONCLUSIONS: We identified a novel piRNA that induced AVC through an RNA epigenetic mechanism and provide novel insights into piRNA-directed theranostics in CAVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 23. doi: 10.1161/CIRCULATIONAHA.123.065213. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Calcification of the aortic valve leads to increased leaflet stiffness and consequently results in the development of calcific aortic valve disease (CAVD). However, the underlying molecular and cellular mechanisms of calcification remain unclear. Here, we identified a novel aortic valve calcification-associated PIWI-interacting RNA (piRNA; AVCAPIR) that increases valvular calcification and promotes CAVD progression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using piRNA sequencing, we identified piRNAs contributing to the pathogenesis of CAVD that we termed AVCAPIRs. High-cholesterol diet-fed ApoE<sup>-/-</sup> mice with AVCAPIR knockout were used to examine the role of AVCAPIR in aortic valve calcification (AVC). Gain- and loss-of-function assays were conducted to determine the role of AVCAPIR in the induced osteogenic differentiation of human valvular interstitial cells. To dissect the mechanisms underlying AVCAPIR-elicited procalcific effects, we performed various analyses, including an RNA pulldown assay followed by liquid chromatography-tandem mass spectrometry, methylated RNA immunoprecipitation sequencing, and RNA sequencing. RNA pulldown and RNA immunoprecipitation assays were used to study piRNA interactions with proteins.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that AVCAPIR was significantly upregulated during AVC and exhibited potential diagnostic value for CAVD. AVCAPIR deletion markedly ameliorated AVC in high-cholesterol diet-fed ApoE<sup>-/-</sup> mice, as shown by reduced thickness and calcium deposition in the aortic valve leaflets, improved echocardiographic parameters (decreased peak transvalvular jet velocity and mean transvalvular pressure gradient, as well as increased aortic valve area), and diminished levels of osteogenic markers (Runx2 and Osterix) in aortic valves. These results were confirmed in osteogenic medium-induced human valvular interstitial cells. Using unbiased protein-RNA screening and molecular validation, we found that AVCAPIR directly interacts with FTO (fat mass and obesity-associated protein), subsequently blocking its <i>N</i><sup>6</sup>-methyladenosine demethylase activity. Further transcriptomic and <i>N</i><sup>6</sup>-methyladenosine modification epitranscriptomic screening and molecular validation confirmed that AVCAPIR hindered FTO-mediated demethylation of CD36 mRNA transcripts, thus enhancing CD36 mRNA stability through the <i>N</i><sup>6</sup>-methyladenosine reader IGF2BP1 (insulin-like growth factor 2 mRNA binding protein). In turn, the AVCAPIR-dependent increase in CD36 stabilizes its binding partner PCSK9 (proprotein convertase subtilisin/kexin type 9), a procalcific gene, at the protein level, which accelerates the progression of AVC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We identified a novel piRNA that induced AVC through an RNA epigenetic mechanism and provide novel insights into piRNA-directed theranostics in CAVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38258575/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240124131108&v=2.18.0">38258575</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065213>10.1161/CIRCULATIONAHA.123.065213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38258575</guid>
<pubDate>Tue, 23 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Dong Han</dc:creator>
<dc:creator>Tingwen Zhou</dc:creator>
<dc:creator>Lifu Li</dc:creator>
<dc:creator>Yan Ma</dc:creator>
<dc:creator>Shiqi Chen</dc:creator>
<dc:creator>Chunguang Yang</dc:creator>
<dc:creator>Ning Ma</dc:creator>
<dc:creator>Moshi Song</dc:creator>
<dc:creator>Shaoshao Zhang</dc:creator>
<dc:creator>Jie Wu</dc:creator>
<dc:creator>Feng Cao</dc:creator>
<dc:creator>Yongjun Wang</dc:creator>
<dc:date>2024-01-23</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease</dc:title>
<dc:identifier>pmid:38258575</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065213</dc:identifier>
</item>





























</channel>
</rss>